Last reviewed · How we verify

umeclidinium 62.5 µg and vilanterol 25 µg

University of Tennessee Graduate School of Medicine · FDA-approved active Small molecule Quality 3/100

umeclidinium 62.5 µg and vilanterol 25 µg is a Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by University of Tennessee Graduate School of Medicine. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment. Also known as: Anoro Ellipta.

Umeclidinium is a long-acting anticholinergic that blocks muscarinic M3 receptors in airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors, together producing bronchodilation for maintenance treatment of chronic obstructive pulmonary disease.

Umeclidinium is a long-acting anticholinergic that blocks muscarinic M3 receptors in airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors, together producing bronchodilation for maintenance treatment of chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameumeclidinium 62.5 µg and vilanterol 25 µg
Also known asAnoro Ellipta
SponsorUniversity of Tennessee Graduate School of Medicine
Drug classLong-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA)
TargetMuscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Umeclidinium prevents acetylcholine from binding to M3 receptors on airway smooth muscle, reducing bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and promoting smooth muscle relaxation. The combination provides dual bronchodilation through complementary mechanisms, improving airflow and reducing symptoms in COPD patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about umeclidinium 62.5 µg and vilanterol 25 µg

What is umeclidinium 62.5 µg and vilanterol 25 µg?

umeclidinium 62.5 µg and vilanterol 25 µg is a Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) drug developed by University of Tennessee Graduate School of Medicine, indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

How does umeclidinium 62.5 µg and vilanterol 25 µg work?

Umeclidinium is a long-acting anticholinergic that blocks muscarinic M3 receptors in airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors, together producing bronchodilation for maintenance treatment of chronic obstructive pulmonary disease.

What is umeclidinium 62.5 µg and vilanterol 25 µg used for?

umeclidinium 62.5 µg and vilanterol 25 µg is indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

Who makes umeclidinium 62.5 µg and vilanterol 25 µg?

umeclidinium 62.5 µg and vilanterol 25 µg is developed and marketed by University of Tennessee Graduate School of Medicine (see full University of Tennessee Graduate School of Medicine pipeline at /company/university-of-tennessee-graduate-school-of-medicine).

Is umeclidinium 62.5 µg and vilanterol 25 µg also known as anything else?

umeclidinium 62.5 µg and vilanterol 25 µg is also known as Anoro Ellipta.

What drug class is umeclidinium 62.5 µg and vilanterol 25 µg in?

umeclidinium 62.5 µg and vilanterol 25 µg belongs to the Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) class. See all Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA) drugs at /class/long-acting-anticholinergic-and-long-acting-beta-2-agonist-combination-lama-laba.

What development phase is umeclidinium 62.5 µg and vilanterol 25 µg in?

umeclidinium 62.5 µg and vilanterol 25 µg is FDA-approved (marketed).

What are the side effects of umeclidinium 62.5 µg and vilanterol 25 µg?

Common side effects of umeclidinium 62.5 µg and vilanterol 25 µg include Tremor, Headache, Palpitations, Dry mouth, Urinary retention.

What does umeclidinium 62.5 µg and vilanterol 25 µg target?

umeclidinium 62.5 µg and vilanterol 25 µg targets Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol) and is a Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA).

Related